Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Onvansertib in Relapsed Small Cell Lung Cancer
NCT05450965Phase 2Recruiting
- Sponsor
- University of Maryland, Baltimore
- Start
- Jul 2022
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of onvansertib in small cell lung cancer (SCLC), sponsored by University of Maryland, Baltimore. Primary endpoint: Objective Response Rate at 42 months. Started Jul 2022; status: recruiting.
02
Drugs
onvansertib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05450965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05450965.